Search Results

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis.

Not everyone who completes a life sciences Ph.D. wants to continue working in a laboratory or in research. If this is the case for you, here are 12 careers for Ph.D. life scientists outside of the lab.

Brazil is the first Latin American country to now welcome Tru Niagen®, with a strategy focused on reaching both consumers and Health Care Practitioners ChromaDex Corp. announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen® and Tru Niagen® PRO in Brazil, the first Latin American country to welcome the brand.

Mammogen, a leader in women’s health and bellwether subsidiary of early detection parent company IVBH, has announced the successful completion of Clinical Laboratory Improvement Amendments (CLIA) validation for its pioneering plasma-based clinical assay, genTRU-breast, a test designed to detect the earliest stages of breast cancer.

A BioSpace LinkedIn poll showed that just 19% of respondents believe biopharma professionals need Ph.D.s for scientist roles.

ChromaDex Corp. announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea.

Xilio Therapeutics, Inc. announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company’s board of directors.

ChromaDex Launches Tru Niagen ® Immune, Further Expanding Innovative Product Portfolio.